Group items tagged

Within the framework of the For Women in Science partnership between the L'Oréal Foundation and UNESCO, we are launching the 2014 call for nominations for outstanding women scientist form all over the world. Five 100.000$ prizes will be awarded in march 2014 in Paris to five women scientists, one per region, for the contributions of their research, the strength of their commitments and their impact on society. An international Jury of eminent scientists presided in 2013 by the Nobel Prize winner, Ahmed Zewali, makes the final selection.

The New Scholars Program supports projects to help early- to mid-career women scientists balance family responsibilities with demanding academic careers. New Scholars seeks to actively address the attrition rate of talented women scientists caused by work-life balance issues.

The purpose of this Dear Colleague Letter is to advise you about funding opportunities at the National Science Foundation for the research community to propose research projects or workshops that will gather data on the implementation and impacts of recent science policy initiatives including, but not limited to those noted earlier.  Especially encouraged are proposals that will: Develop new, or improve existing, analytical frameworks for evaluating the impacts of federal science policy initiatives; Explore different agencies' approaches to the implementation of particular policies to examine how variations in approach affect the achievement of intended policy outcomes; Collect case-study or quantitative data that facilitate identification of best practices in science and innovation policy implementation.

The Melanoma Research Foundation is accepting applications from emerging and established scientific investigators for research projects that explore new avenues in melanoma biology, prevention and treatments, with the goal of finding a cure. The foundation makes grants in four areas: Career Development Awards, Established Investigator Awards, Career Investigator CURE OM Awards, and Established Investigator CURE OM Awards. Career Development Awards provide funding of up to $50,000 a year for two years to junior investigators who are beginning a research career emphasizing melanoma-related projects and have not yet secured strong federal funding for their research. Established Investigator Awards provide funding of up to $100,000 a year for two years to established melanoma researchers or senior researchers working in closely related fields who wish to move into melanoma research. Career Development CURE OM Awards provide funding of up to $50,000 a year for two years to junior investigators in the ocular/uveal melanoma field. Established Investigator CURE OM Awards provides funding of up to $100,000 a year for two years to established ocular/uveal melanoma researchers, or senior researchers.

The purpose of this Funding Opportunity Announcement (FOA) is to encourage new research into integrative cancer biology by fostering collaborations between investigators currently supported through the Integrative Cancer Biology Program (ICBP) and those currently unaffiliated with the ICBP. These collaborative projects should leverage the existing expertise and resources from within the ICBP research community and combine those with new approaches, technologies or methods to address compelling cancer questions. Therefore, the proposed research projects must involve partnerships between investigators currently supported by ICBP and investigators currently unaffiliated with the program. Applications that focus on projects which neither involve integrative cancer biology research, nor expand individual ICBP investigators' research by adding additional expertise, resources, or approaches, or without affiliation to existing ICBP personnel, are not appropriate to this FOA.

This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), is to encourage research projects which focus on the interactions of carcinogenic pathogens with the human microbiome and the host for the detection of pathogen-induced cancer (DPIC). This FOA encourages research to assess molecular signatures associated with risk and early detection of pathogen-induced cancer and chronic inflammation associated with progression to invasive cancer.

his Funding Opportunity Announcement (FOA) invites research project (R01) applications that combine imaging and biomarkers. The overall objective of this FOA is to facilitate collaborative imaging and biomarker research to improve cancer screening, early cancer detection and diagnosis by integrating multi modality imaging strategies and multiplexed biomarker methodologies.

The Research Experiences for Undergraduates (REU) program supports active research participation by undergraduate students in any of the areas of research funded by the National Science Foundation. REU projects involve students in meaningful ways in ongoing research programs or in research projects specifically designed for the REU program. This solicitation features two mechanisms for support of student research: (1) REU Sites are based on independent proposals to initiate and conduct projects that engage a number of students in research. REU Sites may be based in a single discipline or academic department or may offer interdisciplinary or multi-department research opportunities with a coherent intellectual theme. Proposals with an international dimension are welcome. (2) REU Supplements may be included as a component of proposals for new or renewal NSF grants or cooperative agreements or may be requested for ongoing NSF-funded research projects.

The Alfred P. Sloan Foundation makes grants on six broad subject matters, known within the Foundation as major program areas.  Basic Research STEM Higher Education Public Understanding of Science Economic Performance and the Quality of Life Select National Issues Civic Initiatives

The INSPIRE awards program was established to address some of the most complicated and pressing scientific problems that lie at the intersection of traditional disciplines.  It is intended to encourage investigators to submit bold, exceptional proposals that some may consider to be at a disadvantage in a standard NSF review process; it is not intended for proposals that are more appropriate for existing award mechanisms.

The OCRP Teal Innovator Award supports a visionary individual from any field principally outside of, but not exclusive of, ovarian cancer to focus his/her creativity, innovation, and leadership on ovarian cancer research. The Teal Innovator Award will provide the Principal Investigator (PI) with the funding and freedom to pursue his/her most novel, visionary, high-risk ideas that could significantly impact the field of ovarian cancer research or patient care. The proposed Teal Innovator must be highly recognized in his/her field and present evidence of this recognition. Examples include, but are not limited to, recognition at the level of endowed chair; membership in the National Academy of Sciences, National Academy of Engineering, or Institute of Medicine; Chairmanship of the American Association for Cancer Research; or other national or international recognition.

CAREER: The Faculty Early Career Development (CAREER) Program is a Foundation-wide activity that offers the National Science Foundation's most prestigious awards in support of junior faculty who exemplify the role of teacher-scholars through outstanding research, excellent education and the integration of education and research within the context of the mission of their organizations. Such activities should build a firm foundation for a lifetime of leadership in integrating education and research. NSF encourages submission of CAREER proposals from junior faculty members at all CAREER-eligible organizations and especially encourages women, members of underrepresented minority groups, and persons with disabilities to apply.

The Investigator-Initiated Translational Research Award (IITRA) supports translational research that will develop promising ideas in lung cancer into clinical applications. Translational research may be defined as an integration of basic science and clinical observations. Observations that drive a research idea may originate from a laboratory discovery, population-based studies, or a clinician's firsthand knowledge of patient care. The ultimate goal of translational research is to move a concept or observation forward into clinical application. However, Principal Investigators (PIs) should not view translational research as a one-way continuum from bench to bedside. The research plan must involve a reciprocal flow of ideas and information between basic and clinical science. This mechanism is intended to fund a broad range of translational studies, including, but not limited to, the following: * Studies advancing/translating in vitro and/or animal studies to applications with human samples/cohorts. * Late-stage preclinical work leading to/preparing for a clinical trial, e.g., Investigational New Drug (IND) application submission. * Correlative studies that are associated with an ongoing or completed clinical trial and projects that develop endpoints for clinical trials. Preliminary data to support the feasibility of the research hypotheses and research approaches are required; however, these data do not necessarily need to be derived from studies of lung cancer.

The Idea Development Award promotes new ideas that are still in the early stages of development and have the potential to yield impactful data and new avenues of investigation. This award supports conceptually innovative, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress toward eradicating deaths from lung cancer. Applications should include a well-formulated, testable hypothesis based on strong scientific rationale. Submissions from and partnerships with investigators at military treatment facilities, military labs, and Department of Veterans Affairs (VA) medical centers and research laboratories are strongly encouraged. New Investigators: The FY16 Idea Development Award mechanism encourages applications from independent investigators in the early stages of their careers (i.e., within 10 years of their first faculty appointment, or equivalent). The New Investigator category is designed to allow applicants early in their faculty appointments to compete for funding separately from established investigators. Applications from New Investigators and Established Investigators will be peer and programmatically reviewed separately. Principal Investigators (PIs) using the New Investigator category are strongly encouraged to strengthen their applications by collaborating with investigators experienced in lung cancer research and/or possessing other relevant expertise. It is the responsibility of the applicant to describe how the included collaboration will augment the PI's expertise to best address the research question. All applicants for the New Investigator category must meet specific eligibility criteria as described in Section I.D., Eligibility Information. Preliminary data to support the feasibility of the research hypotheses and research approaches are required; however, these data do not necessarily need to be derived from studies of lung cancer.

This Funding Opportunity Announcement (FOA) encourages basic research into the role of RNA chemical modifications and their corresponding writers, readers and erasers in the initiation and progression of cancer. Chemical modifications of RNA bases have been reported to regulate the fate and function of both coding and noncoding RNAs and are emerging as a critical element of post-transcriptional gene regulation. This FOA will utilize the Exploratory/Developmental (R21) mechanism which supports investigation of novel scientific ideas or new model systems, tools or technologies that have the potential for significant impact on biomedical or biobehavioral research.

The Elsa U. Pardee Foundation funds research to investigators in United States non-profit institutions proposing research directed toward identifying new treatments or cures for cancer. The Foundation particularly encourages grant applications for a one year period which will allow establishment of capabilities of new cancer researchers, or new cancer approaches by established cancer researchers. It is anticipated that this early stage funding by the Foundation may lead to subsequent and expanded support using government agency funding. Project relevance to cancer detection, treatment, or cure should be clearly identified. By design, there are no limits set on the grant amount that can be requested. It must be reasonably and clearly supported by the scope of the project outlined in the application. Applications requesting more than 15% overhead are usually not considered. Papers verifying nonprofit status and relevant human subject and experimental animal treatment approvals from the recipient institution will be requested prior to project initiation. A final report summarizing financial expenditure and research achievement is required.

The purpose of this Funding Opportunity Announcement (FOA) is to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers. The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this FOA) must be focused on cancers of the breast, prostate and other genitourinary organs, and lung. In addition, cancers with rapidly rising incidence.

The PRCRP Career Development Award supports independent, early-career investigators to conduct impactful research with the mentorship of an experienced cancer researcher (i.e., the Designated Mentor) as an opportunity to obtain the funding, guidance, and experience necessary for productive, independent careers at the forefront of cancer research. This award supports impactful research projects with an emphasis on discovery. Under this award mechanism, the early-career investigator is considered the Principal Investigator (PI), and the application should focus on the PI's research and career development. It should be clear that the proposed research is intellectually designed by the PI and not a product of the Designated Mentor.